Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.
| Revenue (TTM) | $33.86M |
| Gross Profit (TTM) | $20.20M |
| EBITDA | $-270.09M |
| Operating Margin | -373.50% |
| Return on Equity | 0.00% |
| Return on Assets | -92.80% |
| Revenue/Share (TTM) | $3.43 |
| Book Value | $-29.54 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 72.10% |
| Shares Outstanding | 0 |
| Float | $6.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |